Rapid Review Quiz: Unusual Vaccine News

Michael Stuart Bronze, MD


February 13, 2023

According to a recent meta-analysis, the beneficial off-target effects of early-life BCG vaccine could prevent atopic eczema. The meta-analysis included three randomized controlled trials involving 5655 children randomly assigned to either early-life intervention BCG Denmark vaccination (n = 2832) or no BCG (n = 2823).

The meta-analyses revealed that the BCG Denmark vaccine had a beneficial effect preventing eczema (risk ratio [RR], 0.89; 95% CI, 0.82-0.98). Subgroup analyses revealed that BCG was more beneficial in male children (RR, 0.84; 95% CI, 0.74-0.95) and children of two atopic parents (RR, 0.81; 95% CI, 0.68-0.97). The researchers concluded that the BCG Denmark vaccine delivered in early life leads to an 11% reduction in the risk for eczema with a greater effect for increasing predisposition.

Learn more about BCG immunotherapy.

This Rapid Review Quiz was excerpted and adapted from the Medscape articles: Flu Vaccination Associated With Reduced Stroke Risk, Haemophilus Influenzae Infections, Data Hint COVID-19 Vax May Improve Immunotherapy Efficacy in Some, Nasopharyngeal Cancer, Atrial Fibrillation, Dementia Pathology, and Bacillus Calmette-Guérin Immunotherapy for Bladder Cancer Overview of BCG Immunotherapy.

Follow Medscape on Facebook, Twitter, Instagram, and YouTube


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.